A number of studies have investigated the association of XRCC3 Thr241Met polymorphism with clinical outcomes of NSCLC receiving platinum-based chemotherapy [13]–[16]; however, the results were quite controversial and inconsistent. Here, XRCC3 is linked to non-small cell lung carcinoma.